26 results
DEFA14A
VERV
Verve Therapeutics Inc
26 Apr 24
Additional proxy soliciting materials
7:56am
must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year’s meeting, you must make
8-K
EX-1.1
VERV
Verve Therapeutics Inc
29 Nov 23
Verve Therapeutics Announces Pricing of Public Offering of Common Stock and Concurrent Private Placement
4:54pm
information (collectively with the pricing information set forth on Annex A, the “Pricing Disclosure Package”): a Preliminary Prospectus dated … the Shares on the terms set forth in the Pricing Disclosure Package. The Company acknowledges and agrees that the Underwriters may offer and sell Shares
DEFA14A
u05cu qc99dnra
28 Apr 23
Additional proxy soliciting materials
7:49am
8-K
EX-99.1
vbtq y80kfg
7 Nov 22
Verve Therapeutics Provides Regulatory Update on VERVE-101 Investigational New Drug Application and Reports Third Quarter 2022 Financial Results
7:00am
8-K
EX-1.1
5h0ym f9c
21 Jul 22
Verve Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
4:46pm
DEFA14A
141mke46 3360ulqa9
29 Apr 22
Additional proxy soliciting materials
7:22am
DEF 14A
4gs07l2gw7j2 fn
29 Apr 22
Definitive proxy
7:01am
10-K
m3xa1mk0knqz86
14 Mar 22
Annual report
7:04am
424B4
6r3ge5qe
17 Jun 21
Prospectus supplement with pricing info
4:50pm
S-1/A
EX-1.1
6jz8pq
14 Jun 21
IPO registration (amended)
6:15am
S-1/A
kr0r6v15 wdeh6d7
14 Jun 21
IPO registration (amended)
6:15am